XKRX
006490
Market cap25mUSD
Oct 08, Last price
1,400.00KRW
1D
-4.18%
Jan 2017
-17.89%
Name
Inscobee Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating both domestically in South Korea and internationally, Inscobee, Inc. is a diversified enterprise with core businesses in smart grid technology, mobile virtual network operations (MVNO), biotechnology, and distribution. Its smart grid offerings include intelligent power network components such as K2 chips, data concentration units, PLC bridges, modems, and attenuators. The company also oversees freeT, an MVNO that supports other mobile virtual network operators utilizing various underlying mobile networks. In the biotechnology domain, Inscobee provides medications for pain relief, vaccines against cervical cancer and papillomavirus, alongside a range of cosmeceuticals and nutraceuticals. Furthermore, its distribution activities encompass watches and a variety of electrical products, including smart lighting solutions, LED products, and general lighting fixtures. Established in 1970, Inscobee maintains its headquarters in Seoul, South Korea.
Key people
Yin Su Yoo
Chairman, Chief Executive Officer · since 2025
Ja Gap Gu
President, Co-Chief Executive Officer, Director · since 2020
Ho Dong Han
Managing Director · since 2023
Byeong Jin Kim
Managing Director · since 2022
Hyeong Sang Shin
Managing Director · since 2022
Yong Hoe Kim
Internal Auditor · since 2020
Gyeong Nam Kim
Assistant Managing Director · since 2023
Hyeok Jae Lee
Assistant Managing Director · since 2023
Dae Gi Lee
Assistant Managing Director · since 2022
Sang Ho Sul
Assistant Managing Director · since 2022
Gang Jae Lee
Other Non-Executive Director · since 2021
Jeong Gwan Kim
Non-Executive Independent Director · since 2019
Bo Gyun Lee
Non-Executive Independent Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||